References:
Adebayo, D., Mookerjee, R. P. and Jalan, R. (2012) ‘Mechanistic
biomarkers in acute liver injury: Are we there yet?’, Journal of
Hepatology . European Association for the Study of the Liver, 56(5), pp.
1003–1005. doi: 10.1016/j.jhep.2012.01.017.
Aithal, G. P. et al. (2011) ‘Case definition and phenotype
standardization in drug-induced liver injury’, Clinical
Pharmacology and Therapeutics . 2011/05/06, 89(6), pp. 806–815. doi:
10.1038/clpt.2011.58.
Antoine, D. J. et al. (2013) ‘Mechanistic biomarkers provide
early and sensitive detection of acetaminophen-induced acute liver
injury at first presentation to hospital’, Hepatology , 58(2), pp.
777–787. doi: 10.1002/hep.26294.
Antoine, D. J. and Dear, J. W. (2016) ‘How to treat paracetamol overdose
and when to do it’, Expert Review of Clinical Pharmacology .
Taylor & Francis, 9(5), pp. 633–635. doi:
10.1586/17512433.2016.1154786.
Balzano, F. et al. (2015) ‘MiRNA stability in frozen plasma
samples’, Molecules , 20(10), pp. 19030–19040. doi:
10.3390/molecules201019030.
Bethseda (MD): National Institute of Diabetes and Digestive and Kidney
Diseases (2017) ‘LiverTox: Clinical and Research Information on
Drug-Induced Liver Injury [Internet] Roussel Uclaf Causality
Assessment Method (RUCAM) in Drug Induced Liver Injury.’,[Online] . Available at: https://livertox.nih.gov/rucam.html.
Bustin, S. A. et al. (2009) ‘The MIQE guidelines: minimum
information for publication of quantitative real-time PCR experiments.’,Clinical chemistry . Clinical Chemistry, 55(4), pp. 611–22. doi:
10.1373/clinchem.2008.112797.
Caulín, C., Salvesen, G. S. and Oshima, R. G. (1997) ‘Caspase cleavage
of keratin 18 and reorganization of intermediate filaments during
epithelial cell apoptosis’, Journal of Cell Biology , 138(6), pp.
1379–1394. doi: 10.1083/jcb.138.6.1379.
Church, R. J. et al. (2018) ‘Candidate biomarkers for the
diagnosis and prognosis of drug-induced liver injury: An international
collaborative effort.’, Hepatology (Baltimore, Md.) , 00(00), pp.
1–14. doi: 10.1002/hep.29802.
Dear, J. W. et al. (2018) ‘Risk stratification after paracetamol
overdose using mechanistic biomarkers: results from two prospective
cohort studies’, The Lancet Gastroenterology and Hepatology ,
3(2), pp. 104–113. doi: 10.1016/S2468-1253(17)30266-2.
European Medicines Agency (2016) Letter of support for
drug-induced liver injury (DILI) biomarker . Available at:
https://www.ema.europa.eu/documents/other/letter-support-drug-induced-liver-injury-dili-biomarker_en.pdf
(Accessed: 8 October 2018).
Food and Drug Administration Centre for Drug Evaluation and Research
(2016) Letter of Support for Drug-Induced Drug-Induced Liver
Injury (DILI) Biomarker(s) . Available at:
https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM517355.pdf
(Accessed: 8 October 2018).
Girling, D. J. (1977) ‘The hepatic toxicity of antituberculosis regimens
containing isoniazid, rifampicin and pyrazinamide’, Tubercle .
Elsevier, 59(1), pp. 13–32. doi: 10.1016/0041-3879(77)90022-8.
Griffith, D. E. et al. (2007) ‘An official ATS/IDSA statement:
Diagnosis, treatment, and prevention of nontuberculous mycobacterial
diseases’, American Journal of Respiratory and Critical Care
Medicine , 175(4), pp. 367–416. doi: 10.1164/rccm.200604-571ST.
Hanley, A. J. G. et al. (2004) ‘Elevations in markers of liver
injury and risk of type 2 diabetes: the insulin resistance
atherosclerosis study.’, Diabetes . American Diabetes Association,
53(10), pp. 2623–32. doi: 10.2337/diabetes.53.10.2623.
Hassan, H. M. et al. (2015) ‘Hepatotoxicity mechanisms of
isoniazid: A mini-review’, Journal of Applied Toxicology , 35(12),
pp. 1427–1432. doi: 10.1002/jat.3175.
Haworth, C. S. et al. (2017) British Thoracic Society
guidelines for the management of non-tuberculous mycobacterial pulmonary
disease (NTM-PD) , Thorax . doi: 10.1136/thoraxjnl-2017-210927.
Karlen, Y. et al. (2007) ‘Statistical significance of
quantitative PCR’, BMC Bioinformatics . BioMed Central, 8(1), p.
131. doi: 10.1186/1471-2105-8-131.
LaDue, J. S. and Wroblewski, F. (1955) ‘The Significance of the Serum
Glutamic Oxalacetic Transaminase Activity Following Acute Myocardial
Infarction’, Circulation , 11(6), pp. 871–877. doi:
10.1161/01.CIR.11.6.871.
Metushi, I., Uetrecht, J. and Phillips, E. (2016) ‘Mechanism of
isoniazid-induced hepatotoxicity: Then and now’, British Journal
of Clinical Pharmacology . 2016/01/17, 81(6), pp. 1030–1036. doi:
10.1111/bcp.12885.
Nabisere, R. et al. (2020) ‘Pharmacokinetics,
SAfety/tolerability, and EFficacy of high-dose RIFampicin in
tuberculosis-HIV co-infected patients on efavirenz- or
dolutegravir-based antiretroviral therapy: Study protocol for an
open-label, phase II clinical trial (SAEFRIF)’, Trials . Trials,
21(1), pp. 1–9. doi: 10.1186/s13063-020-4132-7.
Pettersson, J. et al. (2008) ‘Muscular exercise can cause highly
pathological liver function tests in healthy men.’, British
journal of clinical pharmacology . Wiley-Blackwell, 65(2), pp. 253–9.
doi: 10.1111/j.1365-2125.2007.03001.x.
Ramappa, V. and Aithal, G. P. (2013) ‘Hepatotoxicity Related to
Anti-tuberculosis Drugs: Mechanisms and Management’, Journal of
Clinical and Experimental Hepatology . 2013/03/01, 3(1), pp. 37–49.
doi: 10.1016/j.jceh.2012.12.001.
Sattar, N. et al. (2004) ‘Elevated alanine aminotransferase
predicts new-onset type 2 diabetes independently of classical risk
factors, metabolic syndrome, and C-reactive protein in the west of
Scotland coronary prevention study.’, Diabetes . American Diabetes
Association, 53(11), pp. 2855–60. doi: 10.2337/diabetes.53.11.2855.
Saukkonen, J. J. et al. (2006) ‘An official ATS statement:
Hepatotoxicity of antituberculosis therapy’, American Journal of
Respiratory and Critical Care Medicine . 2006/10/06, 174(8), pp.
935–952. doi: 10.1164/rccm.200510-1666ST.
Senior, J. R. (2012) ‘Alanine Aminotransferase: A Clinical and
Regulatory Tool for Detecting Liver Injury–Past, Present, and Future’,Clinical Pharmacology & Therapeutics . John Wiley & Sons, Ltd,
92(3), pp. 332–339. doi: 10.1038/clpt.2012.108.
Shaughnessy, R. G. et al. (2015) ‘Analysis of biobanked serum
from a mycobacterium avium subsp paratuberculosis bovine infection model
confirms the remarkable stability of circulating mirna profiles and
defines a bovine serum mirna repertoire’, PLoS ONE , 10(12), pp.
1–22. doi: 10.1371/journal.pone.0145089.
Tostmann, A. et al. (2008) ‘Antituberculosis drug-induced
hepatotoxicity: Concise up-to-date review’, Journal of
Gastroenterology and Hepatology . Wiley/Blackwell (10.1111), 23(2), pp.
192–202. doi: 10.1111/j.1440-1746.2007.05207.x.
Vliegenthart, A. D. B. et al. (2015) ‘Comprehensive microRNA
profiling in acetaminophen toxicity identifies novel circulating
biomarkers for human liver and kidney injury’, Scientific
Reports . 2015/10/23, 5(1), p. 15501. doi: 10.1038/srep15501.
Wang, K. et al. (2009) ‘Circulating microRNAs, potential
biomarkers for drug-induced liver injury’, Proceedings of the
National Academy of Sciences . 2009/02/28, 106(11), pp. 4402–4407. doi:
10.1073/pnas.0813371106.
World Health Organization (WHO) (2017) Guidelines for treatment of
drug-susceptible tuberculosis and patient care , WHO press . doi:
10.1586/17476348.1.1.85.
World Health Organization (WHO) (2018) Latent tuberculosis
infection: updated and consolidated guidelines for programmatic
management. , WHO press . doi: 10.1056/NEJMcp021045.
World Health Organization (WHO) (2019) ‘WHO TB Report’, WHO
Library Cataloguing-in-Publication Data World .